Receptor-dependent and Receptor-independent Endocannabinoid Signaling: a Therapeutic Target for Regulation of Cancer Growth

Overview

Journal Life Sci

Publisher Elsevier

Specialties Biochemistry
Biology
Physiology

Date 2012 Oct 17

PMID 23069587

Citations 10

Authors

Rukiyah Van Dross

Eman Soliman

Shalini Jha

Travious Johnson

Somnath Mukhopadhyay

Affiliations

Soon will be listed here.

Abstract

The endocannabinoid system comprises the G-protein coupled CB1 cannabinoid receptor (CB1R) and CB2 cannabinoid receptor (CB2R), their endogenous ligands (endocannabinoids), and the enzymes responsible for their synthesis and catabolism. Recent works have revealed several important interactions between the endocannabinoid system and cancer. Moreover, it is now well established that synthetic small molecule cannabinoid receptor agonist acting on either CB1R or CB2R or both exerts anti-cancer effects on a variety of tumor cells. Recent results from many laboratories reported that the expression of CB1R and CB2R in prostate cancer, breast cancer, and many other cancer cells is higher than that in corresponding non-malignant tissues. The mechanisms by which cannabinoids acting on CB1R or CB2R exert their effects on cancer cells are quite diverse and complex. Further, several studies demonstrated that some of the anti-proliferative and apoptotic effects of cannabinoids are mediated by receptor-independent mechanisms. In this minireview we provide an overview of the major findings on the effects of endogenous and/or synthetic cannabinoids on breast and prostate cancers. We also provide insight into receptor independent mechanisms of the anti-cancer effects of cannabinoids under in vitro and in vivo conditions.

Citing Articles

Anandamide Inhibits Vascular Smooth Muscle Migration, Endothelial Adhesion Protein Expression and Monocyte Adhesion of Human Coronary Artery Cells.

Blessing E, Teichmann E, Hinz B Cells. 2025; 13(24.

PMID: 39768198 PMC: 11727187. DOI: 10.3390/cells13242108.

Alzheimer's Disease and Cancer: Common Targets.

Yang X, Dai J, Wu C, Liu Z Mini Rev Med Chem. 2023; 24(10):983-1000.

PMID: 38037912 DOI: 10.2174/0113895575263108231031132404.

Insights into the effects of the endocannabinoid system in cancer: a review.

Fraguas-Sanchez A, Martin-Sabroso C, Torres-Suarez A Br J Pharmacol. 2018; 175(13):2566-2580.

PMID: 29663308 PMC: 6003657. DOI: 10.1111/bph.14331.

Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents.

Ladin D, Soliman E, Griffin L, Van Dross R Front Pharmacol. 2016; 7:361.

PMID: 27774065 PMC: 5054289. DOI: 10.3389/fphar.2016.00361.

The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.

Morell C, Bort A, Vara D, Ramos-Torres A, Rodriguez-Henche N, Diaz-Laviada I Prostate Cancer Prostatic Dis. 2016; 19(3):248-57.

PMID: 27324222 PMC: 5411672. DOI: 10.1038/pcan.2016.19.

References

Patsos H, Hicks D, Dobson R, Greenhough A, Woodman N, Lane J . The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut. 2005; 54(12):1741-50. PMC: 1774787. DOI: 10.1136/gut.2005.073403. View

Mimeault M, Pommery N, Wattez N, Bailly C, Henichart J . Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate. 2003; 56(1):1-12. DOI: 10.1002/pros.10190. View

Bari M, Battista N, Fezza F, Finazzi-Agro A, Maccarrone M . Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J Biol Chem. 2005; 280(13):12212-20. DOI: 10.1074/jbc.M411642200. View

Thors L, Bergh A, Persson E, Hammarsten P, Stattin P, Egevad L . Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One. 2010; 5(8):e12275. PMC: 2924377. DOI: 10.1371/journal.pone.0012275. View

Jin S, Zhou F, Katirai F, Li P . Lipid raft redox signaling: molecular mechanisms in health and disease. Antioxid Redox Signal. 2011; 15(4):1043-83. PMC: 3135227. DOI: 10.1089/ars.2010.3619. View

Ramer R, Brune K, Pahl A, Hinz B . R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. Biochem Biophys Res Commun. 2001; 286(5):1144-52. DOI: 10.1006/bbrc.2001.5518. View

Kozak K, Crews B, Morrow J, Wang L, Ma Y, Weinander R . Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002; 277(47):44877-85. DOI: 10.1074/jbc.M206788200. View

Hermanson D, Marnett L . Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev. 2011; 30(3-4):599-612. PMC: 3366283. DOI: 10.1007/s10555-011-9318-8. View

DeMorrow S, Glaser S, Francis H, Venter J, Vaculin B, Vaculin S . Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem. 2007; 282(17):13098-113. DOI: 10.1074/jbc.M608238200. View

10.

Qamri Z, Preet A, Nasser M, Bass C, Leone G, Barsky S . Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther. 2009; 8(11):3117-29. PMC: 4128286. DOI: 10.1158/1535-7163.MCT-09-0448. View

11.

Sarfaraz S, Afaq F, Adhami V, Mukhtar H . Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005; 65(5):1635-41. DOI: 10.1158/0008-5472.CAN-04-3410. View

12.

Guindon J, Hohmann A . The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol. 2011; 163(7):1447-63. PMC: 3165955. DOI: 10.1111/j.1476-5381.2011.01327.x. View

13.

Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano A, Laezza C . The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol. 2006; 70(4):1298-306. DOI: 10.1124/mol.106.025601. View

14.

Bisogno T, Katayama K, Melck D, Ueda N, De Petrocellis L, Yamamoto S . Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. Eur J Biochem. 1998; 254(3):634-42. DOI: 10.1046/j.1432-1327.1998.2540634.x. View

15.

Cravatt B, Demarest K, Patricelli M, Bracey M, Giang D, Martin B . Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001; 98(16):9371-6. PMC: 55427. DOI: 10.1073/pnas.161191698. View

16.

Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G . Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2004; 313(1):352-8. DOI: 10.1124/jpet.104.078980. View

17.

Yu M, Ives D, Ramesha C . Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem. 1997; 272(34):21181-6. DOI: 10.1074/jbc.272.34.21181. View

18.

Hamtiaux L, Hansoulle L, Dauguet N, Muccioli G, Gallez B, Lambert D . Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PLoS One. 2011; 6(10):e26823. PMC: 3203169. DOI: 10.1371/journal.pone.0026823. View

19.

Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M . Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 1999; 141(1):118-26. DOI: 10.1210/endo.141.1.7239. View

20.

Saario S, Laitinen J . Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol. 2007; 101(5):287-93. DOI: 10.1111/j.1742-7843.2007.00130.x. View